Twist Bioscience CorpTWSTEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
TWST Q1 FY2026 Key Financial Metrics
Revenue
$103.7M
Gross Profit
$54.0M
Operating Profit
$-32.9M
Net Profit
$-30.5M
Gross Margin
52.0%
Operating Margin
-31.7%
Net Margin
-29.4%
YoY Growth
16.9%
EPS
$-0.50
Twist Bioscience Corp Q1 FY2026 Financial Summary
Twist Bioscience Corp reported revenue of $103.7M (up 16.9% YoY) for Q1 FY2026, with a net profit of $-30.5M (up 3.4% YoY) (-29.4% margin). Cost of goods sold was $49.7M, operating expenses totaled $86.9M.
Key Financial Metrics
| Total Revenue | $103.7M |
|---|---|
| Net Profit | $-30.5M |
| Gross Margin | 52.0% |
| Operating Margin | -31.7% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
Twist Bioscience Corp Q1 FY2026 revenue of $103.7M breaks down across 5 segments, led by Industrial Chemicals at $37.2M (35.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Industrial Chemicals | $37.2M | 35.9% |
| Diagnostics | $35.3M | 34.1% |
| Food Or Agriculture | $12.8M | 12.4% |
| Academic Research | $12.2M | 11.8% |
| Health Care | $6.1M | 5.9% |
Income Statement
| Q1 2026 | |
|---|---|
| Revenue | $103.7M |
| YoY Growth | 16.9% |
Balance Sheet
| Q1 2026 | |
|---|---|
| Assets | $638.1M |
| Liabilities | $182.0M |
| Equity | $456.1M |
Cash Flow
| Q1 2026 | |
|---|---|
| Operating CF | $-24.8M |